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tjovin@gwdg.deFilamentous aggregates formed by a-synuclein are a prominent and
presumably key etiological factor in Parkinson’s and other neuro-
degenerative diseases characterized by motor disorders. Numerous studies
have demonstrated that various environmental and intracellular factors
affect the fibrillation properties of a-synuclein, e.g. by accelerating the
process of assembly. Histones, the major component and constituent of
chromatin, interact specifically with a-synuclein and enhance its fibrillation
significantly. Here, we report that another component of chromatin,
double-stranded DNA (dsDNA), either linear or supercoiled, also interacts
with wild-type a-synuclein, leading to a significant stimulation of
a-synuclein assembly into mature fibrils characterized by a reduced lag
phase. In general, the morphology of the fibrils remains unchanged in the
presence of linear dsDNA. Electron microscopy reveals that DNA forms
various types of complexes upon association with the fibrils at their surface
without distortion of the double-helical structure. The existence of these
complexes was confirmed by the electrophoresis, which also demonstrated
that a fraction of the associated DNA was resistant to digestion by
restriction endonucleases. Fibrils assembled from the a-synuclein mutants
A30P and A53T and the C-terminally truncated variants (encoding amino
acid residues 1–108 or 1–124) also form complexes with linear dsDNA.
Possible mechanisms and implications of dsDNA–a-synuclein interactions
are discussed.
q 2004 Elsevier Ltd. All rights reserved.
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Neurodegenerative diseases such as Parkinson’s
(PD) disease, dementia with Lewy bodies, multiple
system atrophy and others are associated with the
formation of filamentous inclusions (deposits)
assembled mainly from a-synuclein, to which a
primary pathophysiological role is ascribed.1–6
Human a-synuclein is an 140 amino acid residue
protein consisting of three distinct regions: (a) an




ing author:(b) a hydrophobic NAC region (residues 61–95);
and (c) a very acidic C terminus (residues 96–140).
a-Synuclein is a member of the family of
“natively unfolded” proteins lacking an ordered
secondary structure in solution under physiological
conditions.7 The functional importance of this
property is unclear, although it has been established
that it plays an important role in molecular
recognition.8 It has been proposed that proteins or
functional regions thereof can exist in three
(possibly four8) thermodynamic states, i.e. random
coil, molten globule, or ordered form and protein
function can arise from any of these states or
transitions between them.9 Furthermore, it was
suggested that natively unfolded proteins, and in
particular a-synuclein, may exhibit distinct
structural features (entirely or partly) due to
binding of various ligands or varying environ-
mental conditions.10–12 Thus, instead of adopting ad.
930 Interaction of a-Synuclein with dsDNAunique, i.e. singular, conformation, natively
unfolded proteins may exist as an ensemble of
alternative structures biased under the influence of
environmental factors.9,13–16
The principal ordered (aggregated) state of
a-synuclein is characterized by a fibrillar
morphology in which a-synuclein (or at least its
central part) adopts a b-sheet conformation.17,18 In
general, the in vitro aggregates resemble material
derived from disease-affected brains.17,19–21 Mature
fibrils have a regular structure up to several
micrometres in length, either untwisted or twisted
in a right-handed or left-handed orientation, with a
characteristic width/height ofw10 nm,22,23 but the
detailed structure of the mature fibrils is not
known. Presumably due to the structural plasticity
of a-synuclein (and similar to other amyloid
proteins), aggregated states exhibit a great morpho-
logical diversity. Thus, at low pH or in the presence
of high concentrations of cations, a-synuclein forms
amorphous aggregates.24,25 By means of electron
(EM) and scanning probe microscopy (SPM) tech-
niques, bead-like structures with a characteristic
size (height) of 2–6 nm were detected.19,26–29 In
addition, pore-like annular structuresw7–10 nm in
diameter26,30,31 and tubular30 aggregates were
found. Evidence exists for the formation of fibrils
of smaller size (height).19,27
As a consequence of the structural flexibility of
a-synuclein, many different ligands modulate its
transition to an aggregated state, generally acting to
accelerate the reaction. Examples are heparin and
other glycosaminoglycans,32 metal cations,24,25 pes-
ticides,33 fatty acids and anionic detergents.34
Polyamines (putrescine, spermine, spermidine)
also accelerate aggregation dramatically by virtue
of their interaction with the highly negatively
charged C terminus of the protein.11,35,36
It has been reported that nucleic acids interact
with different amyloid peptides (b-amyloid, tau
protein, prion peptides) and modulate their
aggregation.37–45 In many cases a stimulatory effect
of nucleic acids on aggregation (fibrillation) of the
proteins was found. Nucleic acids can induce
structural changes (unfolding or a transition from
an a-helical form into a b-sheet isoform) in prion
peptides by forming stable complexes, which can
catalyze and modulate further polymerization.40,43
However, using EM, Nandi et al. failed to detect
amyloid fibrils associated with nucleic acid.40
Aggregated b-amyloid peptides Ab(1-40) and
Ab(25-35) associate with double-stranded DNA
(dsDNA), although no interaction was detected
with the monomeric forms.37 In addition, b-amyloid
peptide Ab(25-35) can convert a supercoiled DNA
into an open circle in the presence of ferrous ions.38
In contrast to the b-amyloid peptides, the aggrega-
tion process of a-synuclein has been regarded as
unmodulated by nucleic acids (tRNA, total RNA,
dsDNA).32
Here, we present evidence for the interaction of
wild-type a-synuclein, A30P and A53T mutants,
and C terminus-truncated fragments with dsDNA.The fibrillation of wild-type a-synuclein is notably
accelerated by linear dsDNA, and mature fibrils
remain associated with the DNA. We hypothesize
that dsDNA serves as a template facilitating the
assembly of a-synuclein into mature fibrils.Results
Preliminary EM experiments indicated that incu-
bation of wild-type a-synuclein with dsDNA led to
the formation of regular mature fibrils with which
DNA remained associated. In order to analyze this
phenomenon in detail we monitored the kinetics of
a-synuclein aggregation by means of a thioflavin-T
(ThioT) binding assay. ThioT interacts with aggre-
gated a-synuclein, leading to a significant increase
in fluorescence intensity. In the absence of DNA the
kinetics were much slower relative to that in the
presence of DNA (Figure 1A). The experimental





where a(t) is the fraction of aggregated a-synuclein,
kapp is the effective rate constant of fibrillation and a
is a parameter reflecting the nucleation processes
determined mainly by the dissociation constant of
the nucleation center. According to this model, the
time, t½, needed to reach the midpoint of the
reaction, i.e. aZ0.5, is given by t1=2zlnðaÞ=kapp. It
is seen that kapp remained unchanged (within
experimental errors), but that t½ decreased signifi-
cantly in the presence of DNA (Figure 1B).
A small initial fluorescence signal for the incu-
bations with DNA could be attributed to the
interaction of ThioT with free DNA. Indeed, in the
absence of protein (but in the presence of DNA) the
fluorescence exceeded that of ThioT alone and
remained stable for several days (not shown),
indicating the formation of a direct dye–DNA
complex.42,46 The gradual decrease of the signal to
wzero at w25 hours most probably reflected the
progressive loss of freely accessible DNA, while for
times O25 hours the fluorescence signal arose
from the interaction of ThioT with the aggregated
a-synuclein.
The mature fibrils assembled from wild-type
a-synuclein (at 100 mM) in the absence of DNA
were long and straight with a width of w10 nm
(Figure 2A). When linear dsDNA (30 mg/ml) was
added to the incubation mixture from the outset,
short and long mature fibrils of similar width were
observed. However, almost all DNA molecules
were associated with the fibrils, forming various
types of complexes (Figure 3). The DNA was clearly
visible on dark-field images as thin curved threads
crossing the fibrils at different angles. It was often
impossible to trace the entire contour of the DNA
molecule, as the latter remained associated closely
with the fibril body. The samples for EM imaging
were stained with uranyl acetate, which interacts
Figure 2. Formation of mature fibrils. EM images of a-
synuclein fibrils formed by the wild-type (A), A53T
mutant (B) and A30P mutant (C) after incubation at 37 8C
for several (three to five) days. The concentration of the
protein was 100 mM. Images were acquired in a bright-
field mode. A, Image of negatively stained sample. B and
C, Images of positively stained samples. The scale bar
represents 100 nm.
Figure 1. Kinetics of a-synuclein
aggregation. A, Kinetics of a-
synuclein (100 mM) fibrillation
upon incubation without (C) and
with (B) salmon sperm DNA
(30 mg/ml) at 37 8C with constant
stirring at pH 7.5. At the indicated
times, aliquots were withdrawn,
mixed with ThioT and fluorescence
was measured (excitation 446 nm,
emission 480 nm). The continuous
and broken lines represent fits to
equation (1) according to
Fernandez et al.11 Non-zero values
of fluorescence for the incubation
with DNA for t!25 hours were not
considered for the fits. B, The graph
represents datasets (kapp and t½) calculated from corresponding fits to the a-synuclein fibrillation kinetics in the absence
(C) and in the presence (B) of DNA obtained from three runs for each reaction condition.
Figure 3. Assembly of wild-type a-synuclein into fibrils
in the presence of linear DNA. EM images of various
types of DNA–fibril complexes formed after the incu-
bation of pPGM1/ScaI DNA (30 mg/ml) with a-synuclein
(100 mM) at 37 8C for several (three to five) days. Images
were acquired in an angular dark-field mode. The arrow
on A indicates the complex used for length measure-
ments. The scale bar represents 100 nm.
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Figure 4. Association of wild-type a-synuclein with
dsDNA monitored by gel electrophoresis. The exper-
iments were performed by incubation of pPGM1/EcoRI
DNA (50 mg/ml) with wild-type a-synuclein (20 mM) for
more than five days, then an aliquot was withdrawn and
loaded onto a gel (lane 1);O55% of DNA did not enter the
gel, whereas the rest migrated as naked pPGM1/EcoRI
DNA (reference lane 2). An aliquot from the same mixture
was withdrawn and incubated with a large excess of ScaI
with subsequent treatment with proteinase K/SDS (see
Materials and Methods) and loaded onto lane 3;!10% of
DNA was not cut, as opposed to 100% in the case of non-
complexed DNA (lane 4). The numbers on the left
indicate the size of the DNA fragments (in bp).
932 Interaction of a-Synuclein with dsDNAboth with DNA phosphate groups and a-synuclein
amino acid side groups, thereby obscuring the DNA
within the complexes.
The most unambiguous evidence for the associ-
ation of DNA with fibrils were the DNA molecules
emerging from the ends of fibrils (short or long) and
apparently joining fibrils via their termini. A small
fraction of fibrils (a small percentage of the total
fibril length) linked in this manner formed long
trains (Figure 3B and C). Interestingly, the fibrils in
this case were usually short, in the range of w15–
50 nm, with an inter-fibrillar separation of w10–
40 nm (mean w20 nm). As shown in the insets in
Figure 3B and C, DNA was observed as a thin
thread running either along the fibril axis or the
fibril border. This observation confirmed that DNA
was associated with the fibril surface.
Length measurements of DNA associated with
fibrils (indicated by arrowheads in Figure 3A), i.e.
the length of visible DNA tails and the distance over
which DNA is associated with the fibril surface,
yielded values compatible with the full DNA length
(regardless of the length of the fibril-associated
segment), indicating the absence of significant
distortions of the DNA backbone.
Examination by EM of the incubations with
various DNA and a-synuclein concentrations at
intermediate times, i.e. significantly shorter than
required for the formation of mature fibrils, showed
correlations between the process of fibril growth
and association of DNA with the fibrils. At short
times corresponding to the absence of the fluor-
escence signal (Figure 1), no fibrils were detected,
whereas DNA remained in its unperturbed state,
apparently without bound proteins. In contrast, at
times corresponding to an increase in ThioT signal,
short fibrils similar in width to mature fibrils were
usually detected, and the DNA molecules (all or a
fraction, depending on initial concentrations of
DNA and protein) were associated with the fibrils.
At still longer times the concentration of the fibrils
on the EM support, alone and DNA-associated,
increased progressively. The DNA–fibril complexes
exhibited a similar structure, regardless of the
incubation time (Figures 2 and 3).
Association of linear DNA with mature fibrils
was confirmed by gel electrophoresis. At a DNA
concentration of 50 mg/ml and 20 mM wild-type
a-synuclein,O55% of pPGM1/EcoRI DNA did not
enter the gel, whereas the rest migrated as naked
linear DNA (Figure 4, lanes 1 and 2); this relation-
ship was confirmed by parallel EM examination
(not shown). Furthermore, digestion with a large
excess of ScaI restriction endonuclease, with sub-
sequent treatment with proteinase K in the presence
of 1% (w/v) SDS, showed that !10% of DNA was
resistant to cleavage. The remainder of the DNA
migrated as two distinct bands with mobilities
corresponding to the fragment lengths predicted
from the positions of the EcoRI and ScaI recognition
sites (Figure 4, lanes 3 and 4). The fractional
resistance of the fibril-associated DNA to
endonuclease digestion presumably reflected arandom positioning of the fibrils along the DNA
sequence and variability in the length of the
interaction region.
a-Synuclein fibrils assembled in the presence of
supercoiled DNA were morphologically similar to
those obtained in the absence of DNA or in the
presence of linear DNA, although the major part of
scDNA was associated with the fibrils in a manner
similar to that with the linear counterpart (not
shown).
The association of DNA with a-synuclein fibrils
was not limited to the wild-type protein. Mutants
A53T and A30P47,48 formed long regular fibrils
(twisted and untwisted) w10 nm in width
(Figure 2B and C, respectively) with kinetic
parameters (a and t½) similar to those of wild-type
protein.12 In the presence of linear dsDNA, similar
fibrils were formed, although again a major part of
the DNA was associated with fibrils in a manner
similar to that for wild-type a-synuclein
(Figure 5A–D, respectively). Long trains (similar
to those formed by wild-type) consisting of short
fibrils end-linked by DNA were present as well. In a
few instances, long individual fibrils were associ-
ated side-by-side, an interaction apparently
mediated by the dsDNA (Figure 5C).
a-Synuclein lacking the last 32 or 16 C-terminal
amino acid residues also formed fibrils (Figure 6A
Figure 5. Assembly of A53T and A30P a-synuclein into
fibrils in the presence of linear DNA. EM images of DNA–
fibril complexes formed after the incubation of
pPGM1/ScaI DNA (30 mg/ml) with A53T mutant (A–C)
or A30P mutant (D) at 37 8C for several (three to five)
days. The concentration of protein was 100 mM. Images
were acquired in an angular dark-field mode. The scale
bars represent 100 nm.
Figure 6. Assembly of C terminus truncated a-
synuclein into fibrils in the presence of linear DNA. EM
images of fibrils assembled by 1–108 and 1–124 peptides
(100 mM, respectively) in the absence (A and C, respect-
ively) and in the presence of pPGM1/ScaI DNA (B and D,
respectively) after the incubation at 37 8C for several
(three to five) days. Images were acquired in an angular
dark-field mode. The scale bar represents 100 nm.
Interaction of a-Synuclein with dsDNA 933and C, respectively) with kinetic profiles qualitat-
ively similar to those of the wild-type protein,
although with faster rates.12 The morphology of
individual fibrils was similar to those formed by the
wild-type protein but the distribution of the fibrils
on the surface of the EM grid was very irregular,
most probably due to a tendency to coalesce. In the
presence of DNA, fibrils, w10 nm in width and
slightly shorter, were distributed irregularly over
the EM carbon film. Free DNA was almost absent.
Instead, the DNA was either associated with
individual fibrils (Figure 6B) or within large nets
consisting of numerous relatively short fibrils,
apparently linked by a large number of DNA
molecules (Figure 6D). Fibrils joined into trains at
their termini were clearly visible inside these large
aggregates.The concurrent incubation of dsDNA and
a-synuclein was not a prerequisite for DNA
association with the fibrils. Addition of dsDNA to
preformed fibrils and a relatively short subsequent
incubation (without stirring) at 37 8C for one to
three hours also led to the formation of complexes
without apparent changes of fibril morphology. The
yield of complexes was lower compared to the
incubations in which dsDNA was present from
the very beginning, i.e. w40–50% of linear and
w30–40% of supercoiled molecules were found
associated with fibrils and these fractions did not
increase upon extended incubation (not shown).
The structure of complexes formed by linear DNA
(Figure 7A) or supercoiled DNA (Figure 7B) was
very similar to that described above. However,
despite the fact that DNA molecules were associ-
ated with the termini of the fibrils, train formation
was not detected.Discussion
We show here that dsDNA accelerates the
assembly of a-synuclein into fibrils and remains
associated with the fibrils produced. We hypoth-
esize that dsDNA may act as a template and/or
nucleation catalyst that facilitates assembly of
a-synuclein into fibrils. There are several lines of
evidence supporting this conjecture: (i) a significant
decrease in the half-time (t½) of the aggregation
Figure 7. Association of dsDNA with preformed fibrils.
EM images of the samples obtained after the incubation of
pPGM1/ScaI (A) or sc pPGM1 (B) DNA with preformed
fibrils assembled from the wild-type a-synuclein (see
Figure 2A). Images were acquired in an angular dark-field
mode. The scale bar represents 100 nm.
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of dsDNA; (ii) invariance of the effective rate
constant of fibrillation in the presence or absence
of DNA; (iii) association of DNA with the surface of
the fibrils; (iv) similarity of fibril morphology grown
in the absence and in the presence of dsDNA; (v)
absence of apparent modulations of the DNA
backbone.
A plausible scenario for the DNA stimulatory
effect is the following: In solution, protein
molecules, presented mainly as monomers,49
interact electrostatically with DNA phosphate
groups. DNA interacts most likely with the posi-
tively charged lysine side-chains located primarily
in the N-terminal part and the central region of the
protein; interaction with the negatively charged C
terminus is unlikely. These electrostatic interactions
potentially (i) lead to the formation of non-
sequence-specific complexes with DNA, and
(ii) increase the local concentration of protein.
Both effects, acting in a concerted manner, dramati-
cally increase the probability of dimer formation,the critical nucleation structure needed for fibril
growth.11,49 We cannot exclude the possibility of
specific folding of DNA-bound protein monomers
localized in close register, also leading either to
formation of nucleation centers (dimers) or direct
assembly of proteins into filaments or both. The
latter possibility is very likely, as the DNA
molecules (all or in part depending on the initial
concentrations of DNA and/or protein in solution)
finally associate with the fibrils. This scenario is
consistent with stimulation of a-synuclein fibrilla-
tion detected by polyanions,32 anionic detergents,34
and negatively charged mica surface,29 although the
authors observed aggregates of quite different
morphologies, probably due to the structural
plasticity of the protein. The appearance of the
structures shown in Figure 5C, in which long
individual fibrils were associated side-by-side in a
process mediated by the dsDNA, may be indicative
of a preferential position of positive and negative
charges on the fibril surface. The association of
DNA with the fibrils is relatively strong, conferring
upon the DNA a resistance to digestion by restric-
tion endonuclease.
In mature fibrils, only the central part of the
polypeptide chain (w30 tow100 residues) is highly
ordered and specifically folded, whereas the N
terminus is structurally heterogeneous,18 implying
a localization close to the fibril surface. Thus,
accessible, positively charged lysine side-chains of
the N terminus may be recruited by DNA (linear or
supercoiled) for its interaction with preformed
fibrils. However, the significant difference in the
yield of complexes depending on when DNA was
added to the incubation mixture is indicative of the
involvement of additional factors accounting for the
interaction between DNA and a-synuclein. In this
respect, the interaction of DNA with b-strands of
fibrils is unlikely, as usually in DNA–protein
complexes, b-strands (in N-to-C direction) either
cross or follow the DNA grooves.50 When a b-strand
crosses the minor groove, a significant distortion
of DNA helix is observed; when a b-strand follows
the major groove, the angle between b-strand and
DNA axis should be fixed (w308). Since the
b-strands exhibit an approximately perpendicular
orientation with respect to the fibril axis,17 our
observations do not support either of these
predictions.
The C terminus within a-synuclein fibrils is
unstructured,18 but recent NMR data demonstrate
the presence of a well-defined binding interface in
its native state in solution.11 Some of the C termini
are located on the surface of mature fibrils.17,51
Repulsion between these solution-exposed, highly
negatively charged C termini likely prevents
coalescence of the mature fibrils, thus leading to
the images of non-interacting fibrils. Fibrils
assembled from the C terminus-truncated a-synu-
clein were morphologically similar to those formed
from the wild-type protein, but they exhibited a
strong tendency for aggregation, presumably due to
a lack of repulsive forces. However, DNA was still
Interaction of a-Synuclein with dsDNA 935associated with the fibrils and probably associated
via interactions (at least in part) with the N-terminal
residues.
The integration of fibrils into trains also supports
our conjecture about dsDNA acting as a template
facilitating the processes of nucleation and fibril
assembly. The relatively short length of the seg-
ments constituting the trains, i.e. w15–50 nm, may
be accounted for, in part, by high dsDNA flexibility
relative to that of mature fibrils and leading to a
structural instability of DNA-associated fibrils
above a certain length limit. The relatively small
yield of complexes obtained in incubations with
DNA added a posteriori, i.e. after the formation of
mature fibrils was completed, supports our con-
jecture that DNA flexibility is a factor that partially
prevents the formation of complexes by virtue of
electrostatic interactions over distances comparable
to the DNA persistence length, i.e. w50 nm.
The fibrils assembled from A30P and A53T
mutants47,48 morphologically resembled those
formed with the wild-type protein but exhibited a
helical twist, which was in agreement with EM and
X-ray data.17 It is tempting to speculate that the N
terminus of A30P or A53T assembled fibrils was
also located close to the fibril surface. Thus, the
association of DNA with these proteins and with
assembled fibrils would be quite feasible.
The absence of a modulation effect of nucleic
acids and dsDNA, in particular, on a-synuclein
fibrillation reported by Cohlberg et al.32 most
probably arises from the interaction of ThioT with
the dsDNA,42,46 inasmuch as the authors analyzed
the reactions of fibrillation in an assay containing
10–20 mM ThioT. Our data provide the first experi-
mental evidence documenting the involvement of
dsDNA in a process of a-synuclein fibrillation.
The significance of DNA-induced a-synuclein
fibrillation and DNA association with the fibrils is
unclear at the present time. In the cell, a-synuclein
interacts and/or co-localizes with various proteins
that are components of signaling pathways or are
potentially required for regulation of a-synuclein
functions.4,52 In general, aggregated a-synuclein is
localized in the brain stem and cortical Lewy bodies
and Lewy neurites are located in cytoplasm. Recent
studies show that a-synuclein is present in neuronal
nuclear inclusions and neuritis in multiple system
atrophy in the form of bundled filaments 10–20 nm
in diameter.53 However, the latter are not mem-
brane-bound and are separated from chromatin
aggregates. In this respect, Goers et al.54 provided
evidence for the co-localization of a-synuclein with
histones in the nuclei of nigral neurons from mice
exposed to a toxic insult. The authors measured
the stoichiometry of the histone:a-synuclein
complex (2 : 1) and showed that histones stimulate
a-synuclein fibrillation in vitro.
The interaction of dsDNA with a-synuclein and
its stimulation of assembly into mature fibrils
indicate that both components of chromatin may
have a significant effect on nuclear-translocated
a-synuclein functioning. In particular, a-synucleinmay interact with histone-free, transcriptionally
active DNA segments and therefore lead to a
decreased transcriptional activity of some genes
responding to environmental stimuli. An opposite
effect, i.e. stimulation of transcription by a-synu-
clein sequestering histones, has been proposed by
Goers et al.54 Taken together, our findings and those
of Goers et al. provide evidence that the inter-
action(s) of a-synuclein with DNA and histones
might serve to regulate gene expression.
Due to structural plasticity of a-synuclein and its
disposition to aggregation under the influence of
numerous cellular factors, the mechanisms main-
taining a-synuclein in a soluble form and prevent-
ing its fibrillation are of primary importance. In
brain cells, the synucleins (a and b) account for
w0.1–0.2% of the total protein,1,55 corresponding to
w2!107K4!107 synuclein molecules per cell.
The mass density of the fibrils can be estimated as
w5–10 protein molecules/nm of fibril length
depending on a physical model of filament
structure, e.g. the intertwining of multiple
protofilaments23,56 or a single 10 nm filament.18,23
The latter would correspond to w5!103–1!104
protein molecules per 1 mm of fibril length.
Assuming that the fibrils can be packed tightly
into a cube 1 mm on a side, the number of
a-synuclein molecules would be w108, a value
close to the estimated total number of molecules in
the cell. It is worth noting that the size of Lewy
bodies is in the range of w5–15 mm3, implying that
they may contain almost all of the a-synuclein
molecules present in the cell. Furthermore, in a cell
with a volume of w2–4 pl, the average synuclein
concentration is w4–40 mM, a value close to the
critical concentration sufficient for fibril growth.57
Assuming that all the a-synuclein molecules are
concentrated in the nucleus, the concentration
would be about five times higher, i.e. w20–
200 mM. Neuronal nuclear inclusions are different
in size and shape, with characteristic sizes of a few
tenths of a micrometre or close to a micrometre,53
thus potentially accounting for a significant fraction
of the total amount of a-synuclein in a cell. These
considerations indicate that minute variations in
local synuclein concentration or the presence of
factors enhancing its fibrillation, e.g. DNA or
histones, may stimulate significantly the aggrega-
tion of a-synuclein into fibrillar structures, imply-
ing that effective mechanisms preventing
unnecessary or occasional conversion of a soluble
a-synuclein into insoluble isoforms must exist in
both the cytoplasm and the nucleus.Materials and MethodsExpression and purification of proteins
Recombinant human wild-type, A53T and A30P
a-synuclein were expressed and purified as described,25
using plasmid pT7-7 encoding for the proteins (courtesy
of the Lansbury laboratory, Harvard Medical School,
936 Interaction of a-Synuclein with dsDNACambridge, MA). The carboxy-terminally truncated
a-synuclein fragments syn(1-108) and syn(1-124) were
amplified by PCR from full-length wild-type a-synuclein
and subcloned into pT7-7. The sequence was confirmed
by DNA sequencing. Expression and purification of the
truncated proteins was performed essentially as
described for full-length a-synuclein.25 The identity of
all proteins was verified by mass spectroscopy. Protein
concentrations were determined with the bicinchoninic
acid (BCA) assay and validated by absorbance measure-
ments at 275 nm using an extinction coefficient of
1400 MK1 cmK1 per tyrosine residue.
DNA
Salmon sperm DNA (Sigma) was dissolved in 10 mM
Tris–HCl (pH 7.5), 50 mM NaCl. Supercoiled pPGM1
(a derivative of pBluescript SK IICDNA, w3000 bp)
DNA was obtained as described.58 pPGM1 digested with
ScaI was extracted with phenol and precipitated with
ethanol. All DNA samples were finally purified by using
a Superose 12 column (SMART system, Amersham
Pharmacia Biotech, Sweden) equilibrated with 10 mM
Tris–HCl (pH 7.5), 50 mM NaCl.
In vitro fibril formation
Fibrils were generated by incubation of a solution
(200–300 ml) containing protein at a concentration of
20–100 mM in 25 mM Tris–HCl (pH 7.5) and DNA
(where indicated). Incubation was carried out at 37 8C in
glass vials under constant stirring with micro Teflon-
coated stir bars using a multiple stirrer Telesystem HP15S
(Variomag) at 300 rpm. For kinetic measurements wild-
type a-synuclein (100 mM) was incubated with salmon
sperm DNA (30 mg/ml). For EM experiments,
pPGM1/ScaI or pPGM1/EcoRI DNA was added to a
final concentration of 20–50 mg/ml and incubations were
continued until the formation of mature fibrils occurred
(several days). Aliquots were withdrawn at different
times (approximately every six to ten hours) and used for
EM sample preparation. For the experiments with DNA
and mature fibrils, pPGM1/ScaI or sc pPGM1 DNA was
added to a final concentration of w35 mg/ml and the
incubation continued for one to three hours at 37 8C
without stirring. For gel electrophoresis experiments,
pPGM1/EcoRI DNA (50 mg/ml) was incubated with
wild-type a-synuclein (20 mg/ml) for at least five days.
Kinetics of fibril formation
Kinetics of fibril formation was monitored with the
ThioT assay as described.25 Briefly, 7.5 ml aliquots were
withdrawn from incubation mixtures at various times
and added to 2.0 ml of 5 mM ThioT in 50 mM Na-glycine
(pH 8.2). The final concentration of protein was 0.37 mM.
Fluorescence measurements were carried out on a Cary
Eclipse spectrofluorimeter using 3.5 ml quartz cuvettes
(Hellma) with a 1 cm light-path as described.25
Fluorescence emission spectra were recorded from
465 nm to 600 nm, using excitation at 446 nm, an
integration time of 0.1 second, and both excitation and
emission bandwidths of 10 nm.
Gel electrophoresis
After the formation of fibrils was completed, an aliquot
(10 ml containing 0.5 mg of DNA) was withdrawn from theincubation mixture, supplemented with the ScaI restric-
tion endonuclease (20 units) and the corresponding buffer
and incubated for 2.5 hours at 37 8C. Proteinase K
(100 mg/ml) and SDS (1%, w/v) were added, and
incubation was continued for two hours at 37 8C. Gel
electrophoresis was performed in 1% (w/v) agarose in
40 mM Tris-acetate, 1 mM EDTA (pH 8.0) at 3.5 V/cm for
four hours.Electron microscopy
Samples for EM examination were prepared as
described.25 An aliquot was withdrawn from the mixture
at different times (indicated in the text and Figure
legends) and diluted 50–100-fold in 10 mM Tris–HCl
(pH 7.5), 10 mM NaCl, and placed on a glow-discharged
carbon film attached to an EM grid. After about one
minute of adsorption the grids were rinsed with a few
drops of 2% (w/v) aqueous uranyl acetate, blotted with
filter-paper, and dried. The samples were examined with
a Philips CM12 electron microscope (Philips, The
Netherlands) either in bright-field or angular dark-field
modes (as indicated in the Figure legends). The negatives
were scanned with a DuoScan T2500 scanner (Agfa,
Germany) at 1200 dpi. Measurements of the micrographs
were carried out with the Windows version of NIH Image
(Scion Corporation). For printing, images were flattened
using a high-pass filter with a radius of 250 pixels and
subsequently adjusted for contrast/brightness using
Adobe Photoshop.References
1. Spillantini, M. G. & Goedert, M. (2000). The
a-synucleinopathies: Parkinson’s disease, dementia
with Lewy bodies, and multiple system atrophy. Ann.
N Y Acad. Sci. 920, 16–27.
2. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K.,
Lee, V. M. et al. (1998). Aggregation of a-synuclein in
Lewy bodies of sporadic Parkinson’s disease and
dementia with Lewy bodies. Am. J. Pathol. 152,
879–884.
3. Spillantini, M. G., Schmidt, M. L., Lee, V. M.,
Trojanowski, J. Q., Jakes, R. & Goedert, M. (1997).
a-Synuclein in Lewy bodies. Nature, 388, 839–840.
4. Lucking, C. B. & Brice, A. (2000). a-Synuclein and
Parkinson’s disease. Cell. Mol. Life Sci. 57, 1894–1908.
5. Goedert, M. (2001). a-Synuclein and neurodegenera-
tive diseases. Nature Rev. Neurosci. 2, 492–501.
6. Maries, E., Dass, B., Collier, T. J., Kordower, J. H. &
Steece-Collier, K. (2003). The role of a-synuclein in
Parkinson’s disease: insights from animal models.
Nature Rev. Neurosci. 4, 727–738.
7. Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A.
& Lansbury, P. T., Jr (1996). NACP, a protein
implicated in Alzheimer’s disease and learning, is
natively unfolded. Biochemistry, 35, 13709–13715.
8. Uversky, V. N. (2002). Natively unfolded proteins: a
point where biology waits for physics. Protein Sci. 11,
739–756.
9. Dunker, A. K., Lawson, J. D., Brown, C. J., Williams,
R. M., Romero, P., Oh, J. S. et al. (2001). Intrinsically
disordered protein. J. Mol. Graph. Model. 19, 26–59.
10. Uversky, V. N. (2002). What does it mean to be
natively unfolded? Eur. J. Biochem. 269, 2–12.
11. Fernandez, C. O., Hoyer, W., Zweckstetter, M., Jares-
Erijman, E. A., Subramaniam, V., Griesinger, C. &
Interaction of a-Synuclein with dsDNA 937Jovin, T. M. (2004). NMR of a-synuclein–polyamine
complexes elucidates the mechanism and kinetics of
induced aggregation. EMBO J. 23, 2039–2046.
12. Hoyer, W., Cherny, D., Subramanian, V. & Jovin, T. M.
(2004). Impact of the acidic C-terminal region com-
prising amino acids 109–140 on a-synuclein aggrega-
tion in vitro. Biochemistry, in the press.
13. Dyson, H. J. & Wright, P. E. (2002). Coupling of folding
and binding for unstructured proteins. Curr. Opin.
Struct. Biol. 12, 54–60.
14. Radivojac, P., Obradovic, Z., Smith, D. K., Zhu, G.,
Vucetic, S., Brown, C. J. et al. (2004). Protein flexibility
and intrinsic disorder. Protein Sci. 13, 71–80.
15. Tompa, P. (2002). Intrinsically unstructured proteins.
Trends Biochem. Sci. 27, 527–533.
16. Dobson, C. M. (2003). Protein folding and misfolding.
Nature, 426, 884–890.
17. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M. &
Crowther, R. A. (2000). Fiber diffraction of synthetic
a-synuclein filaments shows amyloid-like cross-b
conformation. Proc. Natl Acad. Sci. USA, 97,
4897–4902.
18. Der-Sarkissian, A., Jao, C. C., Chen, J. & Langen, R.
(2003). Structural organization of a-synuclein fibrils
studied by site-directed spin labeling. J. Biol. Chem.
278, 37530–37535.
19. Conway, K. A., Harper, J. D. & Lansbury, P. T., Jr
(2000). Fibrils formed in vitro from a-synuclein and
two mutant forms linked to Parkinson’s disease are
typical amyloid. Biochemistry, 39, 2552–2563.
20. Giasson, B. I., Uryu, K., Trojanowski, J. Q. & Lee, V. M.
(1999). Mutant and wild type human a-synucleins
assemble into elongated filaments with distinct
morphologies in vitro. J. Biol. Chem. 274, 7619–7622.
21. Hashimoto, M., Hsu, L. J., Sisk, A., Xia, Y., Takeda, A.,
Sundsmo, M. & Masliah, E. (1998). Human recombi-
nant NACP/a-synuclein is aggregated and fibrillated
in vitro: relevance for Lewy body disease. Brain Res.
799, 301–306.
22. Caughey, B. & Lansbury, P. T. (2003). Protofibrils,
pores, fibrils, and neurodegeneration: separating the
responsible protein aggregates from the innocent
bystanders. Annu. Rev. Neurosci. 26, 267–298.
23. Serpell, L. C. (2000). Alzheimer’s amyloid fibrils:
structure and assembly. Biochim. Biophys. Acta, 1502,
16–30.
24. Uversky, V. N., Li, J. & Fink, A. L. (2001). Metal-
triggered structural transformations, aggregation,
and fibrillation of human a-synuclein. A possible
molecular link between Parkinson’s disease and
heavy metal exposure. J. Biol. Chem. 276, 44284–44296.
25. Hoyer, W., Antony, T., Cherny, D., Heim, G., Jovin,
T. M. & Subramaniam, V. (2002). Dependence of
a-synuclein aggregate morphology on solution
conditions. J. Mol. Biol. 322, 383–393.
26. Ding, T. T., Lee, S. J., Rochet, J. C., Lansbury, P. T., Jr
et al. (2002). Annular a-synuclein protofibrils are
produced when spherical protofibrils are incubated in
solution or bound to brain-derived membranes.
Biochemistry, 41, 10209–10217.
27. Conway, K. A., Harper, J. D. & Lansbury, P. T. (1998).
Accelerated in vitro fibril formation by a mutant
a-synuclein linked to early-onset Parkinson disease.
Nature Med. 4, 1318–1320.
28. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T.,
Williamson, R. E. & Lansbury, P. T. (2000). Accelera-
tion of oligomerization, not fibrillization, is a shared
property of both a-synuclein mutations linked toearly-onset Parkinson’s disease: Implications for
pathogenesis and therapy. Proc. Natl Acad. Sci. USA,
97, 571–576.
29. Hoyer, W., Cherny, D., Subramaniam, V. & Jovin, T. M.
(2004). Rapid self-assembly of a-synuclein observed
by in situ atomic force microscopy. J. Mol. Biol. 340,
127–139.
30. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M.,
Nowak, R. J., Walz, T. & Lansbury, P. T., Jr (2002).
a-synuclein, especially the Parkinson’s disease-
associated mutants, forms pore-like annular and
tubular protofibrils. J. Mol. Biol. 322, 1089–1102.
31. Malisauskas, M., Zamotin, V., Jass, J., Noppe, W.,
Dobson, C. M. & Morozova-Roche, L. A. (2003).
Amyloid protofilaments from the calcium-binding
protein equine lysozyme: formation of ring and linear
structures depends on pH and metal ion concen-
tration. J. Mol. Biol. 330, 879–890.
32. Cohlberg, J. A., Li, J., Uversky, V. N. & Fink, A. L.
(2002). Heparin and other glycosaminoglycans stimu-
late the formation of amyloid fibrils from a-synuclein
in vitro. Biochemistry, 41, 1502–1511.
33. Manning-Bog, A. B., McCormack, A. L., Li, J.,
Uversky, V. N., Fink, A. L. & Di Monte, D. A. (2002).
The herbicide paraquat causes up-regulation and
aggregation of a-synuclein in mice: paraquat and
a-synuclein. J. Biol. Chem. 277, 1641–1644.
34. Necula, M., Chirita, C. N. & Kuret, J. (2003). Rapid
anionic micelle-mediated a-synuclein fibrillization
in vitro. J. Biol. Chem. 23, 23.
35. Antony, T., Hoyer, W., Cherny, D., Heim, G., Jovin,
T. M. & Subramaniam, V. (2003). Cellular polyamines
promote the aggregation of a-synuclein. J. Biol. Chem.
278, 3235–3240.
36. Goers, J., Uversky, V. N. & Fink, A. L. (2003).
Polycation-induced oligomerization and accelerated
fibrillation of human a-synuclein in vitro. Protein Sci.
12, 702–707.
37. Ahn, B. W., Song, D. U., Jung, Y. D., Chay, K. O.,
Chung, M. A., Yang, S. Y. & Shin, B. A. (2000).
Detection of b-amyloid peptide aggregation using
DNA electrophoresis. Anal. Biochem. 284, 401–405.
38. Jang, J. H. & Surh, Y. J. (2002). b-Amyloid induces
oxidative DNA damage and cell death through
activation of c-Jun N terminal kinase. Ann. N Y
Acad. Sci. 973, 228–236.
39. Kampers, T., Friedhoff, P., Biernat, J., Mandelkow,
E. M. & Mandelkow, E. (1996). RNA stimulates
aggregation of microtubule-associated protein tau
into Alzheimer-like paired helical filaments. FEBS
Letters, 399, 344–349.
40. Nandi, P. K., Leclerc, E., Nicole, J. C. & Takahashi, M.
(2002). DNA-induced partial unfolding of prion
protein leads to its polymerisation to amyloid.
J. Mol. Biol. 322, 153–161.
41. Nandi, P. K. & Leclerc, E. (1999). Polymerization of
murine recombinant prion protein in nucleic acid
solution. Arch. Virol. 144, 1751–1763.
42. Nandi, P. K. (1998). Polymerization of human prion
peptide HuPrP 106–126 to amyloid in nucleic acid
solution. Arch. Virol. 143, 1251–1263.
43. Cordeiro, Y., Machado, F., Juliano, L., Juliano, M. A.,
Brentani, R. R., Foguel, D. & Silva, J. L. (2001). DNA
converts cellular prion protein into the b-sheet
conformation and inhibits prion peptide aggregation.
J. Biol. Chem. 276, 49400–49409.
44. Gabus, C., Auxilien, S., Pechoux, C., Dormont, D.,
Swietnicki, W., Morillas, M. et al. (2001). The prion
938 Interaction of a-Synuclein with dsDNAprotein has DNA strand transfer properties similar
to retroviral nucleocapsid protein. J. Mol. Biol. 307,
1011–1021.
45. Gabus, C., Derrington, E., Leblanc, P., Chnaiderman,
J., Dormont, D., Swietnicki, W. et al. (2001). The prion
protein has RNA binding and chaperoning properties
characteristic of nucleocapsid protein NCp7 of HIV-1.
J. Biol. Chem. 276, 19301–19309.
46. Canete, M., Villanueva, A., Juarranz, A. & Stockert,
J. C. (1987). A study of interaction of thioflavine T with
DNA: evidence for intercalation. Cell. Mol. Biol. 33,
191–199.
47. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber,
M., Kosel, S. et al. (1998). Ala30Pro mutation in the
gene encoding a-synuclein in Parkinson’s disease.
Nature Genet. 18, 106–108.
48. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide,
S. E., Dehejia, A., Dutra, A. et al. (1997). Mutation in
the a-synuclein gene identified in families with
Parkinson’s disease. Science, 276, 2045–2047.
49. Krishnan, S., Chi, E. Y., Wood, S. J., Kendrick, B. S., Li,
C., Garzon-Rodriguez, W. et al. (2003). Oxidative
dimer formation is the critical rate-limiting step
for Parkinson’s disease a-synuclein fibrillogenesis.
Biochemistry, 42, 829–837.
50. Tateno, M., Yamasaki, K., Amano, N., Kakinuma, J.,
Koike, H., Allen, M. D. & Suzuki, M. (1997). DNA
recognition by b-sheets. Biopolymers, 44, 335–359.
51. Crowther, R. A., Daniel, S. E. & Goedert, M. (2000).
Characterisation of isolated a-synuclein filaments
from substantia nigra of Parkinson’s disease brain.
Neurosci. Letters, 292, 128–130.52. Dev, K. K., Hofele, K., Barbieri, S., Buchman, V. L. &
van der Putten, H. (2003). Part II: a-synuclein and its
molecular pathophysiological role in neurodegenera-
tive disease. Neuropharmacology, 45, 14–44.
53. Lin, W. L., DeLucia, M. W. & Dickson, D. W. (2004).
a-Synuclein immunoreactivity in neuronal nuclear
inclusions and neurites in multiple system atrophy.
Neurosci. Letters, 354, 99–102.
54. Goers, J., Manning-Bog, A. B., McCormack, A. L.,
Millett, I. S., Doniach, S., Di Monte, D. A. et al. (2003).
Nuclear localization of a-synuclein and its interaction
with histones. Biochemistry, 42, 8465–8471.
55. Shibayama-Imazu, T., Okahashi, I., Omata, K.,
Nakajo, S., Ochiai, H., Nakai, Y. et al. (1993). Cell
and tissue distribution and developmental change of
neuron specific 14 kDa protein (phosphoneuroprotein
14). Brain Res. 622, 17–25.
56. Khurana, R., Ionescu-Zanetti, C., Pope, M., Li, J.,
Nielson, L., Ramirez-Alvarado, M. et al. (2003).
A general model for amyloid fibril assembly based
on morphological studies using atomic force
microscopy. Biophys. J. 85, 1135–1144.
57. Wood, S. J., Wypych, J., Steavenson, S., Louis, J. C.,
Citron, M. & Biere, A. L. (1999). a-synuclein fibrillo-
genesis is nucleation-dependent. Implications for the
pathogenesis of Parkinson’s disease. J. Biol. Chem. 274,
19509–19512.
58. Cherny, D. I., Striker, G., Subramaniam, V., Jett, S. D.,
Palecek, E. & Jovin, T. M. (1999). DNA bending due to
specific p53 and p53 core domain–DNA interactions
visualized by electron microscopy. J. Mol. Biol. 294,
1015–1026.Edited by M. Yaniv(Received 29 March 2004; received in revised form 27 August 2004; accepted 30 September 2004)
